Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

CD36 deficiency induced by antiretroviral therapy.

Serghides L, Nathoo S, Walmsley S, Kain KC.

AIDS. 2002 Feb 15;16(3):353-8.

PMID:
11834946
2.

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.

Blümer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP.

AIDS. 2008 Jan 11;22(2):227-36.

PMID:
18097225
3.

Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B.

Clin Infect Dis. 2005 Oct 15;41(8):1186-95. Epub 2005 Sep 13.

PMID:
16163639
4.

Increased CD36 expression on circulating monocytes during HIV infection.

Meroni L, Riva A, Morelli P, Galazzi M, Mologni D, Adorni F, Galli M.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):310-3.

PMID:
15735450
5.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
6.
7.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
8.

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D; 089 Study Group..

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7.

PMID:
17971713
9.

Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study.

Viganò A, Brambilla P, Pattarino G, Stucchi S, Fasan S, Raimondi C, Cerini C, Giacomet V, Zuccotti GV, Bedogni G.

Clin Drug Investig. 2009;29(2):101-9. doi: 10.2165/0044011-200929020-00004.

PMID:
19133705
10.

Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.

Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, Murphy R, Thompson M, White AC Jr, Wolfe P, McMillan FI, Hanna GJ.

Clin Infect Dis. 2007 Mar 1;44(5):749-54. Epub 2007 Jan 25.

PMID:
17278071
11.
12.

Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.

Guest JL, Ruffin C, Tschampa JM, DeSilva KE, Rimland D.

Pharmacotherapy. 2004 Jun;24(6):727-35.

PMID:
15222662
13.

Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

Rudin C, Burri M, Shen Y, Rode R, Nadal D; Pediatric Infectious Disease Group of Switzerland.; Swiss Mother and Child HIV Cohort Study (MoCHiV)..

Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

PMID:
18382386
14.

Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.

Wilson ME, Sengoku T, Allred KF.

J Cell Biochem. 2008 Apr 1;103(5):1598-606.

PMID:
17879945
15.

Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.

Cameron DW, Becker S, King MS, da Silva B, Klein C, Tokimoto D, Foit C, Calhoun D, Bernstein B, Hanna GJ.

J Antimicrob Chemother. 2007 May;59(5):957-63. Epub 2007 Mar 9.

PMID:
17350990
16.

Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.

Lagathu C, Bastard JP, Auclair M, Maachi M, Kornprobst M, Capeau J, Caron M.

Antivir Ther. 2004 Dec;9(6):911-20.

PMID:
15651750
17.

Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.

Resino S, Palladino C, Lorente R, Micheloud D, Bellón JM, Larru B, Gutiérrez MD, de José MI, Polo R, Muñoz-Fernández MA; Spanish Group of Pediatric HIV Infection..

Pediatr Infect Dis J. 2010 Aug;29(8):774-7. doi: 10.1097/INF.0b013e3181db741b.

PMID:
20375850
18.

Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.

Kline MW, Rugina S, Ilie M, Matusa RF, Schweitzer AM, Calles NR, Schwarzwald HL.

Pediatrics. 2007 May;119(5):e1116-20. Epub 2007 Apr 9.

PMID:
17420261
19.

Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.

Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy AM, Cames C, Sow PS, Ndoye I, Delaporte E, Simondon KB.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):224-30. doi: 10.1097/QAI.0b013e31819c16f4.

PMID:
19339897
20.

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

Sáez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E, Pelton S, Ramilo O, Cahn P, Chadwick E, Allen U, Arpadi S, Castrejón MM, Heuser RS, Kempf DJ, Bertz RJ, Hsu AF, Bernstein B, Renz CL, Sun E.

Pediatr Infect Dis J. 2003 Mar;22(3):216-24.

PMID:
12634581

Supplemental Content

Support Center